Scarica l'app Stockscreener
6.05
5.47%
-0.35
Dopo l'orario di chiusura:
6.02
-0.03
-0.50%
Precedente Chiudi:
$6.40
Aprire:
$6.4
Volume 24 ore:
7,734
Relative Volume:
0.18
Capitalizzazione di mercato:
$44.14M
Reddito:
-
Utile/perdita netta:
$-101.87M
Rapporto P/E:
-4.2908
EPS:
-1.41
Flusso di cassa netto:
$-83.46M
1 W Prestazione:
+2.72%
1M Prestazione:
-4.42%
6M Prestazione:
-4.18%
1 anno Prestazione:
-27.37%
Intervallo 1D:
$6.05
$6.40
Intervallo di 1 settimana:
$5.855
$6.57
Portata 52W:
$5.202
$11.35
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta KZR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.05 | 44.14M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
Major Clinical Development Update: Stanford Expert Reveals Future of Zetomipzomib in Autoimmune Hepatitis - StockTitan
Objective long/short (KZR) Report - Stock Traders Daily
Kezar Life Sciences files for $400M mixed securities shelf - MSN
Autoimmune Hepatitis Market Growth to Accelerate in Forecast - openPR
Kezar Life Sciences Files $400 Million Mixed Securities Shelf -February 05, 2025 at 05:55 pm EST - Marketscreener.com
Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Update - Defense World
Kezar reports preliminary year-end financial position - Investing.com
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar stock falls 11% after board rejects Concentra offer (update) - MSN
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):